Patient Information - Neuroendocrine Cancer Advanced - Lanreotide

Overview

• Lanreotide is a hormone drug used for patients with neuroendocrine tumours to control symptoms such as diarrhea and flushing.
• Treatment involves injections every 4 weeks, primarily administered in the buttock or by the patient in the upper, outer thigh.
• Requires refrigeration.

Treatment Schedule

• Day 1: Lanreotide injection
  • Administered by nurse or doctor, or self-administered.
  • Duration: Approximately 5 minutes.

When to Seek Medical Help

• Immediate actions required for symptoms like high fever, severe chills, shortness of breath, uncontrolled vomiting or diarrhea, chest pain, or general unwellness.

Monitoring and Tests

• Regular blood tests may be necessary.
• Diabetic patients need to monitor blood sugar levels closely, with potential medication adjustments.

Side Effects

• Immediate (hours to days): Nausea, vomiting, flatulence, headache, injection-site reactions.
• Early (days to weeks): Diarrhea, constipation, stomach pain, high blood sugar levels, slow heart rate.
• Late (weeks to months): Hypothyroidism, gallstones, vitamin deficiencies.
• Management includes medication, dietary adjustments, and informing medical personnel of concerning symptoms.

General Advice

• Risk of blood clots; seek medical attention for symptoms indicative of thrombosis.
• Discuss all medications and vaccinations with a healthcare provider.
• Maintain a healthy diet, avoid untreated water, and discuss alcohol use with a doctor.
• Consider fertility issues and use contraception during treatment.
• Avoid pregnancy and breastfeeding during treatment.
• Discuss changes in sex life and emotions with healthcare providers.
• Encouraged to quit smoking and stay physically active.

Additional Resources

• Contact numbers for emergencies and support services.
• Educational resources and links for further information on neuroendocrine tumours and general cancer support.

Important Contacts

• Emergency departments, doctors, and cancer support telephone lines.

Review Dates

• First approved: 23 October 2020
• Last reviewed: 31 October 2023
• Next review: 31 December 2027

Note: Consult with your healthcare team for personalized advice and information. This document is a guide and not exhaustive of all potential situations.